AIM ImmunoTech Inc
AIM
AMX
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
0.92
USD
0.02
(2.00%)
Optionable: No Market Cap: 37 M 90-day average vol: 521,518
Previous close: 0.902 Open: 0.9166 Bid: 0.97 Ask: 0.97
52 week range
0.55 2.40
Last updated: Friday 27th May 2022
Valuation
Price per Sales TTM ($) | 269.12 |
Price per Book TTM ($) | 0.91 |
PE Ratio (TTM) | -2.50 |
Book Value per Share ($) | 1.17 |
5 Year PE Range-3.9 |
Returns
7 Day Return | -2.13% | |
1 Month Return | -10.68% | |
3 Month Return | 35.29% | |
1 Year Return | -56.40% | |
3 Year Return | -83.43% | |
5 Year Return | -96.33% | |
YTD Return | 0.00% |
Risk
Custom Beta One Year | 0.82 |
Custom Beta Three Years | -0.37 |
Beneish M Score | -4.22 |
Altman Z Score | 25.95 |
Financial Health
Technicals
RSI (14 Day) | 43.06 |
14 Day SMA ($) | 0.96 |
14 Day EMA ($) | 0.96 |
Money Flow Index | 72.15 |
Average True Range | 0.08 |
50 Day SMA ($) | 1.03 |
200 Day SMA ($) | 1.31 |
ADX | 22.13 |
MACD | -0.02 |
Growth
Free Cash Flow QoQ Growth | 66.48% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 50.00% |
Revenue QoQ Growth | 51.52% |
EPS YoY Growth | 0.00% |
Profitability
Return on Assets TTM (%) | -31.53 |
Profit Margin TTM (%) | -14118.5 |
Return on Equity TTM (%) | -33.03 |
Return on Capital TTM (%) | -31.99 |
Interest Coverage Ratio | -284.50 |
Gross Margin TTM (%) | -529.6 |
AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer
Yahoo Finance 3/3/2022
AIM ImmunoTech (AIM) Investor Presentation - Slideshow
Seeking Alpha 1/26/2022
AIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar
Yahoo Finance 1/26/2022
AIM ImmunoTech reports positive data from phase1/2 trial in ovarian cancer
Seeking Alpha 1/24/2022
AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer
Yahoo Finance 1/24/2022
AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference
Yahoo Finance 1/19/2022
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
Yahoo Finance 1/12/2022
AIM ImmunoTech’s Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza
Yahoo Finance 12/9/2021
AIM ImmunoTech CEO to Participate in Two Upcoming Investor Conferences
Yahoo Finance 12/6/2021
AIM ImmunoTech EPS in-line
Seeking Alpha 11/16/2021
AIM ImmunoTech Provides Third Quarter 2021 Business Update
Yahoo Finance 11/16/2021
AIM ImmunoTech submits IND and Fast Track application for Ampligen in pancreatic cancer
Seeking Alpha 10/19/2021
AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer
Yahoo Finance 10/19/2021
AIM ImmunoTech to explore Ampligen as intranasal COVID therapy after positive safety data
Seeking Alpha 10/6/2021
AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy
Yahoo Finance 10/6/2021
AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer
Yahoo Finance 10/4/2021
AIM ImmunoTech inks clinical trial agreement for Phase 2a Human Challenge Trial of Ampligen
Seeking Alpha 9/30/2021
AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses
Yahoo Finance 9/30/2021
AIM ImmunoTech submits FDA Pre-IND application for mid-stage Ampligen COVID-19 trials
Seeking Alpha 9/28/2021
| NA |
|---|
| could not broadcast input array from shape (20) into shape (0) |
|---|
AIM Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 213000 | 150000 | 197000 | 133000 | 92000 | 437000 | 367000 | 140000 | 163000 |
| Cost of sales | 1 M | 367000 | 109000 | 408000 | -195000 | 172000 | 6000 | 101000 | 73000 |
| Gross operating profit | -2 M | -1 M | -1 M | -1 M | -1 M | -746000 | -517000 | -753000 | -643000 |
| Selling Gen & administrative expense | 9 M | 8 M | 9 M | 7 M | 8 M | 7 M | 6 M | 7 M | 9 M |
| Research & development expense | 10 M | 8 M | 9 M | 8 M | 5 M | 4 M | 5 M | 5 M | 6 M |
| Operating income | -20 M | -17 M | -19 M | -17 M | -14 M | -11 M | -11 M | -12 M | -15 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 1 M | 167000 | 995000 | 1 M | 6 M | 3 M | 2 M | 3 M | 1 M |
| Pre-tax Income (EBT) | -17 M | -16 M | -17 M | -15 M | -8 M | -8 M | -10 M | -9 M | -14 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from total operations | -17 M | -16 M | -17 M | -15 M | -8 M | -8 M | -10 M | -9 M | -14 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -17 M | -16 M | -17 M | -15 M | -8 M | -8 M | -10 M | -9 M | -14 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -17 M | -16 M | -17 M | -15 M | -8 M | -8 M | -10 M | -9 M | -14 M |
| Depreciation | 683000 | 867000 | 1 M | 1 M | 1 M | 1 M | 878000 | 792000 | 733000 |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -17 M | -15 M | -16 M | -14 M | -6 M | -7 M | -8 M | -8 M | -13 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -63.36 | -52.8 | -47.52 | -31.68 | -14.96 | -12.76 | -9.77 | -2.62 | -0.45 |
| Diluted EPS total | -63.36 | -52.8 | -47.52 | -31.68 | -14.96 | -12.76 | -9.77 | -2.62 | -0.45 |
Top MarketXLS Rank stocks
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!